Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables…
| Price | $9.37 |
|---|---|
| Market cap | $391.76M |
| Sector | Healthcare |
| Industry | Medical - Devices |
| Exchange | NASDAQ |
| 52-week range | 4.79-11.58 |
| Beta | 0.97 |
Explore SENS's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.